Summary
The anticancer alkaloid vindesine (VDS) was conjugated to four mouse monoclonal antibodies recognizing human tumor-associated antigens. The antibodies were 96.5 (antimelanoma, IgG2a); 791T/36 (antiosteogenic sarcoma, IgG2b); 11.285.14, and 14.95.55 (anticarcinoembryonic antigen, IgG1 and IgG2a respectively). Conjugates VDS-96.5 and VDS-791T/36 were tested in vitro and shown to be specifically cytotoxic for target cells expressing the appropriate antigen. The in vivo effects of the antibodies and conjugates were tested against human tumor xenografts in athymic or immunodeprived mice using multiple treatments. Conjugate VDS-96.5 retarded the initial growth of a melanoma xenograft, whereas free antibody was without effect. Similarly, VDS-791T/36 but not free antibody retarded the growth of osteogenic sarcoma 791T. The most marked antitumor effects observed were those obtained with VDS conjugates of the anti-CEA antibodies against a colorectal tumor xenograft. Antibody 14.95.55 suppressed tumor growth both alone and as a VDS conjugate, whereas 11.285.14 produced only a slight effect alone but an almost complete and lasting suppression of tumor growth as a VDS conjugate. Free VDS had little effect at nontoxic levels. Acute studies showed that VDS-11.285.14 conjugate was considerably less toxic than free VDS in Balb/c mice.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Brown JP, Nishiyama K, Hellström I, Hellström KE (1981) Structural characterization of human melanoma-associated antigen p.97 with monoclonal antibodies. J Immunol 127:539–546
Conrad RA, Cullinan GJ, Gerzon K, Poore GA (1979) Structure activity relationships of dimeric catharanthus alkaloid. 2. Experimental anti-tumor activities of N-substituted desacetyl vinblastine amide (Vindesine) sulphates. J Med Chem 22:391–400
Corvalan JRF, Axton CA, Brandon DR, Smith W, Woodhouse CS (1984) Classification of anti-CEA monoclonal antibodies. Protides of the Biological Fluids 31:921–924
Dillman RO, Beauregard JC, Sobol RE, Royston I, Bartholomew RM, Hagen PS, Halpern SP (1983) Complications associated with in vivo administration of anti-CEA murine monoclonal antibodies in patients with advanced colorectal carcinoma. Proc Am Ass Cancer Res, p 217
Embleton MJ, Gunn B, Byers VS, Baldwin RW (1981) Antitumour reactions of monoclonal antibody against a human osteogenic-sarcoma cell line. Br J Cancer 43:582–587
Embleton MJ, Rowland GF, Simmonds RG, Jacobs E, Marsden CH, Baldwin RW (1983) Selective cytotoxicity against human tumour cells by a vindesine-monoclonal antibody conjugate. Br J Cancer 47:43–49
Farrands PA, Perkins AC, Pimm MV, Embleton MJ, Hardy JG, Baldwin RW, Hardcastle JD (1983) Radioimmunodetection of human colorectal cancers by an anti-tumor monoclonal antibody. Lancet 1:397–400
Gold P, Freeman SO (1965) Demonstration of tumour-specific antigens in human colonic carcinomata by immunological tolerance and absorption techniques. J Exp Med 121:439–462
Hellström I, Hellström KE (1971) Colony inhibition and cytotoxicity assays. In: Bloom BR, Glade PR (eds) In vitro methods in cell-mediated immunity. Academic Press, New York, pp 409–414
Herlyn D, Koprowski H (1982) IgG2a monoclonal antibodies inhibit human tumour growth through interaction with effector cells. Proc Natl Acad Sci USA 79:4761–4765
Hockey M, Ford C, Newman C, Corvalan JRF, Rowland GF, Stokes H, Thompson H, Fielding JWL (1983) The immunohistochemical localisation of carcinoembryonic antigen (CEA) with a monoclonal antibody in gastric adenocarcinomas. Br J Surg 70:300
Johnson JR, Ford CHJ, Newman CE, Woodhouse CS, Rowland GF, Simmonds RG (1981) A vindesine-anti-CEA conjugate cytotoxic for human cells in vitro. Br J Cancer 44:472–475
Larson SM, Brown JP, Wright PW, Carrasquillo JA, Hellström I, Hellström KE (1983) Imaging of melanoma with 131I-labelled monoclonal antibodies. J Nuclear Med 24:123–129
Pimm MV, Embleton MJ, Perkins AC, Price MR, Robins RA, Robinson G, Baldwin RW (1982) In vivo localisation of anti-osteogenic sarcoma 791T monoclonal antibody in osteogenic sarcoma xenografts. Int J Cancer 30:75–85
Rowland GF, Simmonds RG, Corvalan JRF, Baldwin RW, Brown JP, Embleton MJ, Ford CHJ, Hellström KE, Hellström I, Kemshead JT, Newman CE, Woodhouse CS (1983) Monoclonal antibodies for targeted therapy with vindesine. Protides of the Biological Fluids 30:375–379
Rowland GF, Corvalan JRF, Axton CA, Gore VA, Marsden CH, Smith W, Simmonds RG (1984) Suppression of growth of a human colorectal tumour in nude mice by vindesine-monoclonal antibody conjugates. Protides of the Biological Fluids 31:783–786
Todd GC, Gibson WR, Morton DM (1976) Toxicology of vindesine (desacetyl vinblastine amide) in mice, rats, and dogs. J Toxicol Environ Health 1:843–850
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Rowland, G.F., Axton, C.A., Baldwin, R.W. et al. Antitumor properties of vindesine-monoclonal antibody conjugates. Cancer Immunol Immunother 19, 1–7 (1985). https://doi.org/10.1007/BF00199304
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00199304